Document:

exv10w29

 

Exhibit 10.29

2004 Stock Incentive Plan

First, that the Title of the Plan is amended to read as follows:

	 	 	 	“The Corporate Executive Board Company 2004 Stock Incentive Plan (as amended July 18,
2005, and December 22, 2006 and February 21, 2007).”

Second, which the first sentence of Section 6(d) (Duration and Exercise or Termination of Option)
of the Plan is amended to read as follows:

	 	 	 	“The Administrator shall have the right to make the timing of the ability to exercise any
Option subject to continued employment, the passage of time and/or such performance
requirements as deemed appropriate by the Administrator, provided that in no event shall any
Option become exercisable sooner than one (1) year after the date of grant except in the
event of the Participant’s death, or Total and Permanent Disablement or, in the
case of Nonemployee Directors, Retirement or, in the case of any optionee, a change of
control (as defined in the applicable Award Agreement).”exv10w1

 

Exhibit 10.1

***Text Omitted and Filed Separately

Confidential Treatment Requested

Under 17 C.F.R. §§ 200.80(b)(4) and 240.24b-2

LICENSE AGREEMENT

     THIS LICENSE AGREEMENT (this “Agreement”) dated as of March 14, 2007 (the
“Effective Date”) is entered into by and between CELL-MATRIX, INC., a Nevada corporation
(“Cell-Matrix”), having a place of business at 2110 Rutherford Road, Carlsbad, California
92008, and TRACON PHARMACEUTICALS, INC., a Delaware corporation (“Tracon”), having a place
of business at 4510 Executive Drive, Suite 330, San Diego, California 92121.

RECITALS

     WHEREAS, Cell-Matrix owns or has rights in the Cell-Matrix Patent Rights and the Technology
(as each is defined below).

     WHEREAS, Cell-Matrix, formerly known as Bio-Management, Inc., obtained certain exclusive
license patent rights pursuant to that certain License Agreement by and between Cell-Matrix and the
University of Southern California (“USC”) effective as of September 14, 1999 (as amended
from time to time, the “USC Agreement”).

     WHEREAS, Cell-Matrix obtained ownership to certain rights in and to modified antibodies
pursuant to that certain Amended and Restated Collaboration Agreement by and between Cell-Matrix
and Applied Molecular Evolution (“AME”) dated as of October 15, 2004 (as amended from time
to time, the “AME Agreement”).

     WHEREAS, Cell-Matrix has obtained certain rights to negotiate and receive a commercial license
grant (with the right to grant sublicenses) to certain production systems pursuant to that certain
Research Evaluation Agreement between Micromet AG (an Affiliate of Cell-Matrix, Inc.) and
[***] made on [***] (as amended from time to time, the “[***] Agreement”).

     WHEREAS, Tracon desires to obtain an exclusive license to the foregoing rights on the terms
and conditions set forth below.

     NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein
contained, the parties hereby agree as follows:

     1. DEFINITIONS

     For purposes of this Agreement, the terms defined in this Section 1 shall have the respective
meanings set forth below:

          1.1 “Affiliate” shall mean, with respect to any Person, any other Person which
directly or indirectly controls, is controlled by, or is under common control with, such Person. A
Person shall be regarded as in control of another Person if it owns, or directly or indirectly
controls, at least fifty percent (50%) of the voting stock or other ownership interest of the other

 

			
	***	 	Certain information on this page has been
omitted and filed separately with the Commission. Confidential treatment has
been requested with respect to the omitted portions.

 

 

Person, or if it directly or indirectly possesses the power to direct or cause the direction
of the management and policies of the other Person by any means whatsoever.

          1.2 “AME” shall have the meaning set forth in the Recitals to this Agreement.

          1.3 “AME Agreement” shall have the meaning set forth in the Recitals to this
Agreement.

          1.4 “BLA” shall mean a Biologics License Application, Product License Application, New
Drug Application, or Abbreviated New Drug Application submitted to the FDA, a Marketing Approval
Application filed with the EMEA, and any corresponding applications in countries or territories
other than the foregoing submitted to the relevant Competent Authority, in each case for marketing
approval of a Product.

          1.5 “Cell-Matrix In-Licenses” shall mean the AME Agreement, [***]
Agreement, the [***] License Agreement, and USC Agreement.

          1.6 “Cell-Matrix Patent Rights” shall mean (a) the patents and patent applications
listed on Exhibit A hereto, (b) all patents and patent applications in any country of the
world that claim or cover the Technology or its use, in each case in which Cell-Matrix has an
ownership or (sub)licensable interest as of the Effective Date, but excluding the USC Patent Rights
and the [***] Patent Rights, (c) all patents and patent applications in any country of the world to
the extent specifically disclosing or claiming D93 [***], in each case in which Cell-Matrix has an
ownership or (sub)licensable interest during the term of this Agreement, but excluding the USC
Patent Rights and the [***] Patent Rights, (d) all divisions, continuations, and
continuations-in-part, that claim priority to, or common priority with, the patent applications
listed in clauses (a) — (c) above or the patent applications that resulted in the patents described
in clauses (a) — (c) above (but, in the case of continuations-in-part, only to the extent that such
continuations-in-part disclose or claim D93 or, provided that Tracon has exercised its option
pursuant to Section 3.2, [***]), and (e) all patents that have issued or in the future issue from
any of the foregoing patent applications, including utility, model and design patents and
certificates of invention, together with any reissues, renewals, extensions or additions thereto.

          1.7 “Clinical Plan” shall have the meaning set forth in Section 3.9.

          1.8 “Competent Authority(ies)” shall mean, collectively, (a) the governmental entities
in each country or supranational organization that is responsible for the regulation of any Product
intended for use in the Field (including the FDA, the EMEA and the MHLW), or (b) any other
applicable regulatory or administrative agency in any country or supranational organization that is
comparable to, or a counterpart of, the foregoing.

          1.9 “Confidentiality Agreement” shall mean that certain Confidentiality Agreement made
and entered into by Cell-Matrix and Paramount as of July 13, 2006.

 

			
	***	 	Certain information on this page has been
omitted and filed separately with the Commission. Confidential treatment has
been requested with respect to the omitted portions.

-2-

 

          1.10 “D93” shall mean the humanized IgG1 antibody directed against denatured collagen
with the variable domain amino sequence listed in Exhibit B, together with any derivatives,
fragment or modifications of such antibody.

          1.11 “D93 Product” shall mean a Product comprising D93.

          1.12 “Development Milestone” shall have the meaning set forth in Section 8.3.

          1.13 “EMEA” shall mean the European Medicines Agency, or the successor thereto.

          1.14 “FDA” shall mean the Food and Drug Administration of the United States, or the
successor thereto.

          1.15 “Field” shall mean the prevention, treatment, diagnosis, detection, monitoring,
prognosis or predisposition testing for any disease, state or condition in humans or other animals.

          1.16 “First Commercial Sale” shall mean, with respect to any Product, the first sale
of such Product after all applicable marketing and pricing approvals (if any) have been granted by
the applicable Competent Authority of such country.

          1.17 “[***]” shall mean the [***] directed [***] with the [***] listed in
Exhibit C, together with any [***] of such [***].

          1.18 “[***] Product” shall mean a Product comprising [***].

          1.19 “Indication” shall mean any condition or discrete disease pattern in the Field
for which a BLA, supplemental BLA, or similar regulatory filing may be filed.

          1.20 “JSC” shall have the meaning set forth in Section 3.10.

          1.21 “Knowledge” shall mean the [***] (including, the [***] and [***]) of Cell-Matrix,
Micromet, Inc. or any of their respective Affiliates and employees of Cell-Matrix, Micromet, Inc.
or their respective Affiliates with [***] regarding the [***] and [***] regarding the [***].

          1.22 “Licensed IP Rights” shall mean, collectively, the Licensed Patent Rights and the
Licensed Know-How Rights.

          1.23 “Licensed Know-How Rights” shall mean all trade secret and other know-how rights
in which Cell-Matrix has an ownership interest or has a transferable interest, in and to all data,
information, compositions and other technology (including, but not limited to, formulae,
procedures, protocols, techniques and results of experimentation and testing) which are necessary
or useful for Tracon to make, use, develop, sell or seek regulatory approval to market a

 

			
	***	 	Certain information on this page has been
omitted and filed separately with the Commission. Confidential treatment has
been requested with respect to the omitted portions.

-3-

 

Product, or to practice any method or process relating to a Product, and that (a) is at any
time claimed or disclosed in any issued patent or pending patent application within the Cell-Matrix
Patent Rights, or (b) exists as of the Effective Date or during the term of this Agreement to the
extent specifically applicable to D93 [***] or is generated by Cell-Matrix or its Affiliates in the
course of performing activities under this Agreement.

          1.24 “Licensed Patent Rights” shall mean (a) the Cell-Matrix Patent Rights, (b) the
USC Patent Rights, and (c) if Cell-Matrix has obtained a commercial license grant from [***] under
the [***] Agreement pursuant to Section 3.7, the [***] Patent Rights.

          1.25 “[***]” shall have the meaning set forth in the Recitals to this Agreement.

          1.26 “[***] Agreement” shall have the meaning set forth in the
Recitals to this Agreement.

          1.27 “[***] Know-How Rights” shall mean all know-how for which Cell-Matrix obtains a
sublicensable right under the [***] License Agreement.

          1.28 “[***] License Agreement” shall have the meaning as defined in Section 3.7.

          1.29 “[***] Patent Rights” shall mean all patents and patent applications for which
Cell-Matrix obtains a sublicensable right under the [***] License Agreement.

          1.30 “MHLW” shall mean the Ministry of Health, Labour and Welfare of Japan, or the
successor thereto.

          1.31 “Net Sales” shall mean, with respect to any Product, the gross sales price of
such Product invoiced by Tracon, or any of its Affiliates or sublicensees to customers who are not
a sublicensee (or are a sublicensee but are the end users of such Product) less, to the extent
actually paid or accrued by Tracon, or any of its Affiliates or sublicensees (as applicable), (a)
credits, allowances, discounts and rebates to, and chargebacks from the account of, such customers
for nonconforming, damaged, out-dated and returned Product; (b) freight and insurance costs
incurred by Tracon, or any of its Affiliates or sublicensees (as applicable) in transporting such
Product to such customers to the extent separately invoiced; (c) cash, quantity and trade
discounts, rebates and other price reductions for such Product given to such customers under price
reduction programs; (d) sales, use, value-added and other direct taxes incurred on the sale of such
Product to such customers; (e) customs duties, tariffs, surcharges and other governmental charges
incurred in exporting or importing such Product to such customers; and (g) an allowance for
uncollectible or bad debts taken with respect to such Product, in each case as determined in
accordance with generally accepted accounting principles.

          1.32 “Onset” shall mean the first dosing of the first patient in the applicable
clinical trial.

 

			
	***	 	Certain information on this page has been
omitted and filed separately with the Commission. Confidential treatment has
been requested with respect to the omitted portions.

-4-

 

          1.33 “Paramount” shall mean Paramount BioSciences LLC, a New York limited liability
company.

          1.34 “Person” shall mean an individual, corporation, partnership, limited liability
company, trust, business trust, association, joint stock company, joint venture, pool, syndicate,
sole proprietorship, unincorporated organization, governmental authority or any other form of
entity not specifically listed herein.

          1.35 “Phase I Clinical Trial” shall mean a human clinical trial that is intended to
initially evaluate the safety and/or pharmacological effect of a Product in subjects or that would
otherwise satisfy requirements of 21 C.F.R. 312.21(a), or its non-U.S. equivalent.

          1.36 “Phase IIa Clinical Trial” shall mean a human clinical trial that is intended to
evaluate the pharmacokinetics and safety of a Product for a particular indication or indications in
human subjects with the disease or indication under study and establish the dose of a Product or
that would otherwise satisfy the requirements of US 21 C.F.R. §312.21(b) or its non-U.S.
equivalent.

          1.37 “Phase IIb Clinical Trial” shall mean a human clinical trial that is intended to
initially evaluate the efficacy of a Product for a particular indication or indications in human
subjects with the disease or indication under study or that would otherwise satisfy the
requirements of US 21 C.F.R. §312.21(b) or its non-U.S. equivalent.

          1.38 “Phase III Clinical Trial” shall mean a human clinical trial in any country the
results of which could be used to establish safety and efficacy of a Product as a basis for a BLA
or label expansion of a pharmaceutical product or that would otherwise satisfy the requirements of
21 C.F.R. 312.21(c), or its non-US equivalent.

          1.39 “Pivotal Trial” shall mean a Phase IIb Clinical Trial or Phase III Clinical Trial
in any country the results of which could be used to establish safety and efficacy of a Product as
a basis for a BLA or label expansion of a pharmaceutical product.

          1.40 “Product(s)” shall mean any product comprising D93[***] [***].

          1.41 “Registration(s)” shall mean any and all permits, licenses, authorizations,
registrations or regulatory approvals (including BLAs) required and/or granted by any Competent
Authority as a prerequisite to the development, manufacturing, packaging, marketing and selling of
any product.

          1.42 “Royalty Term” shall mean, with respect to each Product in each country, the
period commencing on First Commercial Sale in such country and expiring on a country-by-country
basis on the later of (a) the expiration of the last-to-expire Valid Claim that would be infringed
but for the license granted by this Agreement, by the manufacture, use, offer for sale, sale or
import of such Product in such country, or (b) [***]years following the First Commercial Sale of
such Product in such country.

 

			
	***	 	Certain information on this page has been
omitted and filed separately with the Commission. Confidential treatment has
been requested with respect to the omitted portions.

-5-

 

          1.43 “Sublicense Agreement” shall mean any agreement under which Tracon grants a
sublicense under the license set forth in Section 3.1.

          1.44 “Sublicensing Revenues” shall mean, with respect to any Product, the aggregate
consideration received by Tracon or any of its Affiliates in connection with an agreement under
which Tracon grants a sublicense under any of the rights granted to Tracon under this Agreement to
a Third Party (including upfront fees, annual license fees and milestone payments), but excluding
amounts received by Tracon or any of its Affiliates (i) as [***]under this Agreement or the under
the Cell-Matrix In-Licenses, (ii) to [***] or [***]after the execution of such
sublicense, [***], for such Product; (iii) [***] relating to such Product; or (iv) in consideration
for the [***]in a transaction not made in connection with a Sublicense Agreement. In the case of
any [***]as shall be mutually agreed by the parties.

          1.45 “Successful Completion” shall mean that the applicable Phase I Clinical Trial has
shown a safe and tolerable dose and that the Product had a side effect profile that does not
adversely affect the applicable Product’s eligibility to enter the next phase clinical trial or, if
applicable, to be subject to a BLA.

          1.46 “Technology” shall mean (a) D93 [***], (b) any derivatives, fragment or
modifications of any such antibody, and (c) nucleotide sequences that encode any of the foregoing.

          1.47 “Territory” shall mean all countries of the world.

          1.48 “Third Party” shall mean any Person other than Cell-Matrix or Tracon or any of
their Affiliates.

          1.49 “USC” shall have the meaning set forth in the Recitals to this Agreement.

          1.50 “USC Agreement” shall have the meaning set forth in the Recitals to this
Agreement.

          1.51 “USC Patent Rights” shall mean the “PATENT” and “PATENTS” as defined in the USC
Agreement.

          1.52 “Valid Claim” shall mean (a) a claim of an issued and unexpired patent included
within the Licensed Patent Rights, which has not been held permanently revoked, unenforceable or
invalid by a decision of a court or other governmental agency of competent jurisdiction,
unappealable or unappealed within the time allowed for appeal, and which has not been admitted to
be invalid or unenforceable through reissue or disclaimer or otherwise, and (b) a claim included in
a pending patent application included in the Licensed Patent Rights that is being actively
prosecuted and that has not been canceled, withdrawn from consideration, finally determined to be
unallowable by the applicable governmental authority (from which no appeal is or can be taken), or
abandoned or disclaimed, provided that notwithstanding the foregoing clause (b), in the event that
a pending claim in a pending patent application does not issue in an issued

 

			
	***	 	Certain information on this page has been
omitted and filed separately with the Commission. Confidential treatment has
been requested with respect to the omitted portions.

-6-

 

patent within [***]after the earliest date from which such patent application
claims priority, such a pending claim shall not be a Valid Claim, unless and until such pending
claim subsequently issues in an issued patent, in which case such claim shall be reinstated and be
deemed to be a Valid Claim as of the date of issuance of such patent in accordance with clause (a)
above.

     2. REPRESENTATIONS AND WARRANTIES

          2.1 Mutual Representations and Warranties. Each party hereby represents and warrants
to the other party, as of the Effective Date, as follows:

               2.1.1 Such party is a corporation duly organized, validly existing and in good standing under
the laws of the state in which it is incorporated.

               2.1.2 Such party (a) has the corporate power and authority and the legal right to enter into
this Agreement and to perform its obligations hereunder, and (b) has taken all necessary corporate
action on its part to authorize the execution and delivery of this Agreement and the performance of
its obligations hereunder. This Agreement has been duly executed and delivered on behalf of such
party, and constitutes a legal, valid, binding obligation, enforceable against such party in
accordance with its terms (except as limited by applicable bankruptcy, insolvency, reorganization,
moratorium or other laws of general application affecting enforcement of creditors’ rights, or as
limited by general principles of equity that restrict the availability of equitable remedies).

               2.1.3 All necessary consents, approvals and authorizations of all governmental authorities and
other Persons required to be obtained by such party in connection with this Agreement have been
obtained.

               2.1.4 The execution and delivery of this Agreement and the performance of such party’s
obligations hereunder (a) do not conflict with or violate any requirement of applicable laws or
regulations, and (b) do not conflict with, or constitute a default under, any contractual
obligation of it.

          2.2 Cell-Matrix Representations and Warranties. Cell-Matrix, Micromet, Inc., and
Micromet AG each hereby represent and warrant to Tracon that, to its Knowledge as of the Effective
Date:

               2.2.1 Cell-Matrix (a) is the sole owner or exclusive licensee of the Licensed IP Rights, and
except as Cell-Matrix has expressly informed Tracon in writing prior to the date of this Agreement,
has not granted to any Third Party any license or other interest in the Licensed IP Rights, (b) is
not aware of any Third Party patent, patent application or other intellectual property rights that
would be infringed by making, using or selling Products, except as Cell-Matrix has informed Tracon
in writing prior to the date of this Agreement, and (c) is not aware of any infringement or
misappropriation by a Third Party of the Licensed IP Rights.

 

			
	***	 	Certain information on this page has been
omitted and filed separately with the Commission. Confidential treatment has
been requested with respect to the omitted portions.

-7-

 

               2.2.2 Cell-Matrix has provided Tracon with complete and correct copies of all Cell-Matrix
In-Licenses, and there have been no modifications, amendments or restatements other than as
provided to Tracon prior to the Effective Date. The Cell-Matrix In-Licenses are in full force and
effect in accordance with their terms. After giving effect to this Agreement, there exist no
breaches, defaults or events which would (with the giving of notice, the passage of time or both)
give rise to a breach, default or other right to terminate or modify any Cell-Matrix In-License.
Cell-Matrix has not transferred or granted, and Cell-Matrix shall not transfer or grant, to any
Third Party any license or other interest in the Cell-Matrix In-Licenses that would conflict with
the rights granted to Tracon under this Agreement. With respect to the AME Agreement, Cell-Matrix
does not have any further obligation to AME with respect to, and the negotiation and execution of
this Agreement shall not result in any right accruing to AME pursuant to Section 7.5 of the AME
Agreement. Other than [***] Cell-Matrix has not filed any Registrations with any
Competent Authority for the Product.

          2.3 Tracon Covenant. Tracon covenants and agrees that it shall not knowingly, nor
shall it knowingly cause or permit any Affiliate or sublicensee to, use or practice the Licensed IP
Rights outside of the scope of the licenses granted in this Agreement, and not to knowingly take
any action or knowingly make any omission that would cause Cell-Matrix to default under any of the
Cell-Matrix In-Licenses, or otherwise provide the other party under the applicable Cell-Matrix
In-License the right to terminate such Cell-Matrix In-License.

          2.4 Limitation on Representations or Warranties. Notwithstanding anything to the
contrary in this Agreement, a party shall not be in breach of any representation or warranty made
pursuant to Section 2 to the extent such breach arises directly from any fact or circumstance
actually known by the other party on or prior to the Effective Date.

          2.5 Disclaimer of Warranties. EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH IN SECTION
2 AND SECTION 4.2.1, TRACON AND CELL-MATRIX MAKE NO REPRESENTATIONS AND GRANT NO WARRANTIES,
EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND TRACON AND
CELL-MATRIX EACH SPECIFICALLY DISCLAIMS ANY OTHER REPRESENTATIONS AND WARRANTIES, WHETHER WRITTEN
OR ORAL, EXPRESS, STATUTORY OR IMPLIED, INCLUDING ANY WARRANTY OF QUALITY, MERCHANTABILITY OR
FITNESS FOR A PARTICULAR USE OR PURPOSE OR ANY WARRANTY AS TO THE VALIDITY OF ANY PATENTS OR THE
NON-INFRINGEMENT OF ANY INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES.

     3. LICENSE GRANT

          3.1 Licensed IP Rights. Cell-Matrix hereby grants to Tracon an exclusive license
(with the right to grant sublicenses through multiple tiers) under the Licensed IP Rights to
conduct research and to develop, make, have made, use, offer for sale, sell, import and otherwise
commercialize Products in the Territory for use in the Field.

                    

	 	 	 
	***	 	Certain information on this page has been omitted and filed
separately with the Commission. Confidential treatment has been
requested with respect to the omitted portions.

-8-

 

          3.2
[***] to [***]. Cell-Matrix hereby grants to Tracon an [***]
to obtain an [***] (with the [***]) under the [***]. Tracon may [***] at any time during the term
of this Agreement. Upon receipt of such notice by Cell-Matrix, [***], and the terms of this
Agreement shall apply to such [***] in all respects. Promptly following the [***] and the [***],
Cell-Matrix shall [***] for the [***]then in Cell-Matrix’s possession.

          3.3 Reservation of Rights. Except for the rights expressly provided herein, nothing
contained in this Agreement shall be construed as granting or conveying (expressly, by implication,
or otherwise) to Tracon any license or other rights under any of patent, know-how or other
intellectual property rights of Cell-Matrix or its Affiliates.

          3.4 Sublicenses. Tracon shall, in each Sublicense Agreement, require the sublicensee
to transfer to Cell-Matrix if this Agreement terminates and to Tracon if only such sublicense
terminates (a) documents and materials described in, and to the extent associated with, Section
11.5 held, possessed or transferable by such sublicensee; and (b) all patents and know-how claiming
inventions or discoveries relating to the Products conceived or reduced to practice in the course
of developing or commercializing the Products pursuant to the Sublicense Agreement owned or
sublicensable by such sublicensee (which shall be transferred either by assignment or by license
with rights to further sublicense). Any Sublicense Agreement shall be consistent with the terms
and conditions of this Agreement. Tracon shall (i) provide Cell-Matrix with a copy of each
Sublicense Agreement; (ii) use commercially reasonable efforts to procure the performance by any
sublicensee of the terms of each such Sublicense Agreement, and (iii) be responsible for any breach
of this Agreement that is caused (directly or indirectly) by the performance (or failures to
perform) of its sublicensee. The grant of any such sublicense shall not relieve Tracon of its
obligations under this Agreement, except to the extent they are satisfactorily performed by an
Affiliate or sublicensee. In the event that Tracon, after [***], then [***] shall be [***].

          3.5 USC Agreement. Tracon agrees to be bound by the terms and conditions of the USC
Agreement applicable to “SUBLICENSEES” (as defined in the USC Agreement). If, prior the Effective
Date, Cell-Matrix has not obtained written permission from USC to grant the sublicense under the
USC Patent Rights as set forth in this Agreement, then promptly following the Effective Date
Cell-Matrix shall obtain such written consent from USC. Cell-Matrix shall timely perform in full
all obligations required to be performed by Cell-Matrix under the USC Agreement. Cell-Matrix
promptly shall provide Tracon with copies of all notices and other deliveries received under the
USC Agreement. Without the prior express written consent of Tracon, Cell-Matrix shall not (and
shall take no action or make no omission to) modify or waive any provision of the USC Agreement
that could impair the value of the license and rights under the USC Patent Rights that are granted
to Tracon herein, or to terminate or have terminated the USC Agreement. Within [***] following the
Effective Date, Cell-Matrix shall propose a written amendment to USC that amends the USC Agreement
such that if the USC Agreement [***], USC shall [***] and thereafter Cell-Matrix shall use
reasonable efforts to negotiate and enter into such amendment with USC.

 

			
	***	 	Certain information on this page has been
omitted and filed separately with the Commission. Confidential treatment has
been requested with respect to the omitted portions.

-9-

 

          3.6 AME Agreement. Cell-Matrix shall timely perform in full all obligations required
to be performed by Cell-Matrix under the AME Agreement. Cell-Matrix promptly shall provide Tracon
with copies of all notices and other deliveries received under the AME Agreement. Without the
prior express written consent of Tracon, Cell-Matrix shall not (and shall take no action or make no
omission to) modify or waive any provision of the AME Agreement that could impair the value of the
license and rights under the Cell-Matrix Patent Rights that are granted to Tracon herein, or to
terminate or have terminated the AME Agreement.

          3.7
[***] Agreement. Tracon acknowledges that as of the Effective
Date, Micromet AG’s rights under the [***] Agreement are limited to a non-sublicensable research
and evaluation license grant. Within [***] following the Effective Date, Micromet AG shall
exercise its option to obtain a commercial license under the [***] Agreement and shall cause
Cell-Matrix to use reasonable efforts to seek and obtain from [***] a definitive license agreement
(the “[***] License Agreement”) including a commercial license grant (with the right to
grant sublicenses) under and in accordance with the [***] Agreement, and after obtaining such
license grants, the [***] Patent Rights and [***] Know-How Rights, as applicable, shall be included
within the scope of the Licensed IP Rights. Following the execution of the [***] License
Agreement, Cell-Matrix shall timely perform in full all obligations required to be performed by
Cell-Matrix under the [***] License Agreement. Cell-Matrix promptly shall provide Tracon with
copies of all notices and other deliveries received under the [***] License Agreement. Without the
prior express written consent of Tracon, Cell-Matrix shall not (and shall take no action or make no
omission to) modify or waive any provision of the [***] License Agreement that could impair the
value of the license and rights under the [***] Patent Rights or [***] Know-How Rights, as
applicable, that are granted to Tracon herein, or to terminate or have terminated the [***] License
Agreement.

          3.8 Transfer of Know-How and Product Materials. Promptly following the Effective
Date, Cell-Matrix shall transfer to Tracon all Licensed Know-How Rights that exist in written or
electronic form together with copies of all data, information, reports, protocols, Registrations
(including, without limitation, [***]), and communications with Competent Authorities in each case
with respect to the D93 Product and in existence as of the Effective Date, or in the case of the
[***], on the effective date of [***]. Notwithstanding the foregoing, Cell-Matrix shall timely
file the required annual report to [***] for the current calendar year and transfer such IND
promptly after the filing of such annual report. Cell-Matrix shall make its and its Affiliates’
employees and consultants reasonably available to Tracon (at no cost to Tracon) for consultation as
reasonably necessary to provide an orderly transfer of the foregoing information.

          3.9 Clinical Plan. Following the Effective Date, Tracon shall prepare and provide to
Cell-Matrix a clinical development plan that sets forth Tracon’s intended research, development,
manufacturing and clinical activities for the purpose of obtaining marketing approval of the
Products (the “Clinical Plan”). From time to time during the term of this Agreement, as
Tracon makes any significant changes to its intended development and clinical

 

			
	***	 	Certain information on this page has been
omitted and filed separately with the Commission. Confidential treatment has
been requested with respect to the omitted portions.

-10-

 

activities, but not less than once per calendar year, Tracon shall provide to Cell-Matrix an
updated Clinical Plan.

          3.10 Joint Steering Committee. The parties shall establish a joint steering committee
with at least one (1) representative appointed by each party to review and discuss progress of
activities under the Clinical Plan (the “JSC”). The JSC shall meet on a semi-annual basis
at times and places to be mutually agreed upon in good faith. The purpose of the JSC shall be
solely to oversee such activities, and any decisions of the JSC on matters regarding such
activities shall not be binding on the parties unless approved by all members of the JSC. The JSC
will not have any power to amend this Agreement and will have only such powers as are specifically
delegated to it under this Agreement. If, with respect to a certain matter, there is not unanimity
by all members of the JSC, then the Chief Executive Officers of each party shall meet and attempt
to resolve the matter. If after meeting and attempting to resolve any such matter the Chief
Executive Officers of the parties are unable to resolve the matter, then the [***] shall have the
final decision making authority with respect to such matter. The JSC shall be disbanded upon the
date that is [***] from the Effective Date. In addition, Cell-Matrix shall have the right to
disband the JSC with respect to a Product upon [***] written notice at any time after the
[***] of such Product [***].

          3.11 Technical Assistance. For a reasonable period following completion of the
transfer pursuant to Section 3.8, Cell-Matrix shall provide such technical assistance to Tracon as
Tracon reasonably requests regarding the Licensed IP Rights, D93 Products [***], or Technology.
Tracon shall pay to Cell-Matrix its documented reasonable out-of-pocket costs in providing such
technical assistance, and reimburse Cell-Matrix for time of personnel of Cell-Matrix or its
Affiliates engaged in the performance of such technical assistance at a reasonable cost to be
agreed by the parties.

          3.12 Registrations. Tracon shall file and shall own all Registrations for Products
for use in the Field in each country in the Territory.

     4. PRODUCT SUPPLY

          4.1 Delivery. Promptly following the Effective Date, Cell-Matrix shall sell and
deliver to Tracon the following materials (collectively, the “Materials”):

          (a) [***] of clinical trial grade materials consisting of D93;

          (b) Master cell banks for D93; and

          (c) all associated toxicology and reference material for D93 in Cell-Matrix’s possession or
control.

          4.2 Delivery; Acceptance and Rejection.

 

			
	***	 	Certain information on this page has been
omitted and filed separately with the Commission. Confidential treatment has
been requested with respect to the omitted portions.

-11-

 

               4.2.1 Cell-Matrix shall transfer ownership to the Materials to Tracon at the facility of
[***] (“[***]”) and the parties shall execute such documents as necessary with
[***] to evidence such transfer of ownership, with delivery of the Materials to be deemed made to
Tracon upon such transfer. Cell-Matrix hereby represents and warrants to Tracon that the Materials
shall conform to the applicable specifications set forth in Exhibit D (the
“Specifications”) at the time of such delivery. Tracon shall be responsible for
transferring the Materials to its Third Party storage facility and for all risk of the loss of the
Materials, storing and handling the materials in accordance all applicable requirements to maintain
the quality thereof, and all costs associated for storage of the Materials by [***] or other Third
Party, provided that the parties shall share equally in the cost of shipping of and insurance for
the Materials from the [***] facility to such Third Party. Tracon shall inspect the Materials upon
transfer of ownership, and conduct such testing as it deems appropriate to confirm that the
Materials conform to the Specifications. Any Materials not rejected in writing within [***] after
the date of transfer shall be deemed accepted, except to the extent of any nonconformity with the
Specifications not discoverable through reasonable testing and in existence on the date of delivery
(a “Latent Defect”). If Tracon determines that any Materials do not conform to the
Specifications, it shall promptly provide written notice thereof to Cell-Matrix within the [***]
acceptance period or within [***] of any discovery of any Latent Defect. If Cell-Matrix does not
agree with Tracon’s determination, the Materials shall be submitted for inspection and testing by a
mutually agreed upon independent laboratory, which shall make a final determination binding upon
the parties as to whether the Materials in question met the Specifications as of the date of
delivery. The cost of such testing shall be borne by the party against which the independent
laboratory rules in its determination.

               4.2.2 If Materials are determined to be not conforming to the Specifications in accordance
with the procedures set forth in Section 4.2.1 above, Cell-Matrix shall in its discretion replace
the non-conforming Materials or reduce the applicable payments due under Section 4.3 pro rata of
the quantity of the applicable Materials found to be not conforming. Such replacement or reduction
in payment shall be Tracon’s sole and exclusive remedy in connection with any failure of
Cell-Matrix to deliver Materials that conform to Specifications or with regard to any warranty made
pursuant to Section 4.2.1.

          4.3 Payment Schedule. Tracon shall pay to Cell-Matrix a total of [***] ($[***]) in
the aggregate for the Materials identified in Section 4.1 above, consisting of (a) [***] ($[***])
for the Materials described in Section 4.1(a), (b) [***] ($[***]) for the Materials described in
Section 4.1(b), and (c) [***] ($[***]) for the Materials described in Section 4.1(c). Tracon shall
pay the aggregate amount in accordance with the following payment schedule:

          (i) [***] ($[***]) within [***] of the Effective Date of this Agreement;

          (ii) [***] ($[***]) within [***] following the Effective Date;

          (iii) [***] ($[***]) within [***] following the Effective Date;

 

			
	***	 	Certain information on this page has been
omitted and filed separately with the Commission. Confidential treatment has
been requested with respect to the omitted portions.

-12-

 

          (iv) [***] ($[***]) within [***] following the Effective Date;

          (v) [***] ($[***]) within [***] following the Effective Date;

          (vi) [***] ($[***]) within [***] following the Effective Date;

          (vii) [***] ($[***]) within [***] following the Effective Date; and

          (viii) [***] ($[***]) within [***] following the Effective Date.

     5. FINANCIAL CONSIDERATIONS

          5.1 License Fees. In consideration of the licenses granted hereunder, Tracon shall
make the following non-refundable, non-creditable one-time payments to Cell-Matrix as follows:

                    (a) within [***] following the Effective Date, Tracon shall pay to Cell-Matrix [***] ($[***]),
[***] ($[***]) of which is to be paid by Cell-Matrix to AME pursuant to Section 4.1.5(d) of the AME
Agreement;

                    (b) on the [***] anniversary of the Effective Date, Tracon shall pay to Cell-Matrix [***]
($[***]); and

                    (c) within [***] following the delivery of the [***] pursuant to Section 3.2, Tracon shall pay
to Cell-Matrix [***] ($[***]) which is to be paid by Cell-Matrix to AME pursuant to [***] the AME
Agreement.

          5.2 Royalties. During the applicable Royalty Term for a Product, subject to the terms
and conditions of this Agreement, Tracon shall pay to Cell-Matrix royalties, with respect to each
Product, equal to [***] percent ([***]%) of Net Sales of such Product by Tracon, its Affiliates, or
its sublicensees. Only one royalty shall be owing for a Product regardless of how many Valid
Claims cover such Product. Tracon will be solely responsible for any royalties or other payments
due to any Third Party in order to exercise rights hereunder to make, have made, use, sell, offer
for sale or import any Product (excluding any payments that may be due under the Cell-Matrix
In-Licenses, which are addressed in Section 5.6 below).

          5.3 Combination Products. If a Combination Product (as defined below) is sold, then
for the purpose of calculating royalties owed under this Agreement on sales of the Combination
Product, Net Sales shall be calculated as follows: first, Tracon shall determine the actual Net
Sales of such Combination Product (calculated using the above described deductions) and then such
amount shall be multiplied by the fraction A/(A+B), where A is the weighted (by sales volume)
average invoice price of the actual Product component of such Combination Product, and B is the
weighted (by sales volume) average invoice price of the other active ingredient(s) of such
Combination Product or proprietary delivery device. If the invoice price of either the applicable
Product, the other active ingredient(s) of such Combination Product or the

 

			
	***	 	Certain information on this page has been
omitted and filed separately with the Commission. Confidential treatment has
been requested with respect to the omitted portions.

-13-

 

or proprietary delivery device cannot be determined, Net Sales of such Combination Product
shall be (i) equitably determined by the parties, and (ii) if no agreement can be reached,
submitted to binding arbitration by a single arbitrator under the AAA arbitration rules for
Commercial Disputes. “Combination Product” means [***] a product consisting of a
Product and one or more other active ingredients[***].

          5.4 Sublicensing Revenues. During the applicable Royalty Term for a Product, subject
to the terms and conditions of this Agreement, Tracon shall pay to Cell-Matrix a share of
Sublicensing Revenues as follows:

                    (a) With respect to each agreement entered into by Tracon, its Affiliate or sublicensee prior
to [***] for a particular Product, Tracon shall pay to Cell-Matrix [***] percent ([***]%) of the
applicable Sublicensing Revenues received by Tracon or any of its Affiliates as a result of such
agreement;

                    (b) With respect to each agreement (other than those described in clause (a) above) entered
into by Tracon, its Affiliate or sublicensee prior to [***] for a particular Product, Tracon shall
pay to Cell-Matrix [***] percent ([***]%) of the applicable Sublicensing Revenues received by
Tracon or any of its Affiliates as a result of such agreement;

                    (c) With respect to each agreement (other than those described in clauses (a) or (b) above)
that Tracon, its Affiliate or sublicensee enters into prior to [***] for a particular Product,
Tracon shall pay to Cell-Matrix [***] percent ([***]%) of the applicable Sublicensing Revenues
received by Tracon or any of its Affiliates as a result of such agreement; and

                    (d) With respect to each agreement that Tracon enters into after [***] for a particular
Product, Tracon shall pay to Cell-Matrix [***] percent ([***]%) of the applicable Sublicensing
Revenues received by Tracon or any of its Affiliates as a result of such agreement.

          5.5 Milestones.

               5.5.1 Milestones due for any Product. Tracon shall pay to Cell-Matrix the following
non-refundable, non-creditable one-time milestone payments within [***] following the first
achievement of the applicable milestone event:

	 	$[***] 	 	Successful Completion of the first Phase I Clinical Trial for a Product conducted by
or for Tracon, its Affiliate or sublicensee;
	 
	 	$[***] 	 	Onset of the first Phase IIa Clinical Trial for a Product conducted by or for Tracon,
its Affiliate or sublicensee;
	 
	 	$[***] 	 	Onset of the first Pivotal Trial for a Product conducted by or for Tracon, its
Affiliate or sublicensee;

 

			
	***	 	Certain information on this page has been
omitted and filed separately with the Commission. Confidential treatment has
been requested with respect to the omitted portions.

-14-

 

For the avoidance of doubt, each milestone shall be paid once irrespective of the number of times
such milestone is achieved by one or more Products and the total aggregate milestones payable under
Section 5.5.1 in the aggregate for all Products shall not exceed $[***].

If a milestone event described in Section 5.5.1 is achieved that is subsequent to a preceding
milestone event with respect to which Tracon has not yet made the corresponding milestone payment,
the preceding milestone event is deemed achieved, and the corresponding milestone payment is due
and payable together with the payment of the milestone payment for the subsequent milestone event.

               5.5.2 BLA Acceptance and Approval Milestones due for D93 [***]. Tracon shall pay to
Cell-Matrix the following non-refundable, non-creditable one-time milestone payments within [***]
following [***] the first achievement of the applicable milestone event with a D93 Product, [***]:

	 	$[***] 	 	upon acceptance for review by the FDA of the first BLA submitted by Tracon, its
Affiliate or sublicensee for the first Indication for [***] the D93 Product [***];
	 
	 	$[***] 	 	upon acceptance for review by the EMEA of the first BLA submitted by Tracon, its
Affiliate or sublicensee for the first Indication for [***] the D93 Product [***];
	 
	 	$[***] 	 	upon acceptance for review by the MHLW of the first BLA submitted by Tracon, its
Affiliate or sublicensee for the first Indication for [***] the D93 Product [***];
	 
	 	$[***] 	 	upon acceptance for review by the FDA of the first BLA submitted by Tracon, its
Affiliate or sublicensee for the second Indication for [***] the D93 Product [***];
	 
	 	$[***] 	 	upon acceptance for review by the EMEA of the first BLA submitted by Tracon, its
Affiliate or sublicensee for the second Indication for [***] the D93 Product [***];
	 
	 	$[***] 	 	upon acceptance for review by the MHLW of the first BLA submitted by
Tracon, its Affiliate or sublicensee for the second Indication for [***] the D93
Product [***];
	 
	 	$[***] 	 	upon acceptance for review by the FDA of the first BLA submitted by Tracon, its
Affiliate or sublicensee for the third Indication for [***] the D93 Product [***];

 

			
	***	 	Certain information on this page has been
omitted and filed separately with the Commission. Confidential treatment has
been requested with respect to the omitted portions.

-15-

 

	 	$[***] 	 	 upon acceptance for review by the EMEA of the first BLA submitted by
Tracon, its Affiliate or sublicensee for the third Indication for [***] the D93 Product
[***];
	 
	 	$[***] 	 	upon acceptance for review by the MHLW of the first BLA submitted by Tracon, its
Affiliate or sublicensee for the third Indication for [***] the D93 Product [***];
	 
	 	$[***] 	 	upon receipt by Tracon, its Affiliate or sublicensee of the first approval of the BLA
from the FDA for the first Indication for [***] the D93 Product [***];
	 
	 	$[***] 	 	upon receipt by Tracon, its Affiliate or sublicensee of the first approval of the BLA
from the EMEA for the first Indication for [***] the D93 Product [***];
	 
	 	$[***] 	 	upon receipt by Tracon, its Affiliate or sublicensee of the first approval of the BLA
from the MHLW for the first Indication for [***] a D93 Product [***];
	 
	 	$[***] 	 	upon receipt by Tracon, its Affiliate or sublicensee of the first approval of the BLA
from the FDA for the second Indication for [***] a D93 Product [***];
	 
	 	$[***] 	 	upon receipt by Tracon, its Affiliate or sublicensee of the first approval of the BLA
from the EMEA for the second Indication for [***] a D93 Product [***];
	 
	 	$[***] 	 	upon receipt by Tracon, its Affiliate or sublicensee of the first approval of the BLA
from the MHLW for the second Indication for [***] a D93 Product [***];
	 
	 	$[***] 	 	upon receipt by Tracon, its Affiliate or sublicensee of the first approval of the BLA
from the FDA for the third Indication for [***] a D93 Product [***];
	 
	 	$[***] 	 	upon receipt by Tracon, its Affiliate or sublicensee of the first approval of the BLA
from the EMEA for the third Indication for [***] a D93 Product [***];
	 
	 	$[***] 	 	upon receipt by Tracon, its Affiliate or sublicensee of the first approval of the BLA
from the MHLW for the third Indication for [***] a D93 Product [***];

 

			
	***	 	Certain information on this page has been
omitted and filed separately with the Commission. Confidential treatment has
been requested with respect to the omitted portions.

-16-

 

For the avoidance of doubt, Tracon shall not be obligated to make a milestone payment under
this Section 5.5.2 for a D93 Product [***] in excess of the three (3) milestones described above in
respect of acceptance for review of a BLA submission with each of the FDA, the EMEA and MHLW and
the three (3) milestones described above in respect of BLA approvals by each of the FDA, the EMEA
and MHLW.

               5.5.3 Sales Milestones due for D93 [***]. Tracon shall pay to Cell-Matrix the
following non-refundable, non-creditable one-time milestone payments within [***] following [***]
the first achievement of the applicable milestone event with a D93 Product[***]:

	 	$[***] 	 	on the date that Net Sales of a D93 Product [***] by Tracon, its
Affiliates and sublicensees first equal, in the aggregate, [***] Dollars ($[***]) for
such applicable Product;
	 
	 	$[***] 	 	on the date that Net Sales of a D93 Product [***] by Tracon, its Affiliates and
sublicensees first equal, in the aggregate, [***] Dollars ($[***]) for such applicable
Product;
	 
	 	$[***] 	 	on the date that Net Sales of a D93 Product [***] by Tracon, its Affiliates and
sublicensees first equal, in the aggregate, [***] Dollars ($[***]) for such applicable
Product;
	 
	 	$[***] 	 	on the date that Net Sales of a D93 Product [***] by Tracon, its Affiliates and
sublicensees first equal, in the aggregate, [***] Dollars ($[***]) for such applicable
Product;
	 
	 	$[***] 	 	on the date that Net Sales of a D93 Product [***] by Tracon, its Affiliates and
sublicensees first equal, in the aggregate, [***] Dollars ($[***]) for
such applicable Product; and
	 
	 	$[***] 	 	on the date that Net Sales of a D93 Product [***] by Tracon, its Affiliates and
sublicensees first equal, in the aggregate, [***] Dollars ($[***]) for such applicable
Product.
	 
	 	$[***] 	 	on the date that Net Sales of a D93 Product [***] by Tracon, its Affiliates and
sublicensees first equal, in the aggregate, [***] Dollars ($[***]) for such applicable
Product.

               5.5.4 Notice. Tracon shall notify Cell-Matrix within [***] after the occurrence of an
achievement of each milestone event giving rise to a payment obligation under Sections 5.5.1 and
5.5.2 and within [***] of the end of the applicable calendar quarter during which achievement of
each milestone event giving rise to a payment obligation under Section 5.5.3 occurs.

          5.6 Payments owing under the Cell-Matrix In-Licenses.

 

			
	***	 	Certain information on this page has been
omitted and filed separately with the Commission. Confidential treatment has
been requested with respect to the omitted portions.

-17-

 

               5.6.1 USC Agreement. Subject to the terms and conditions of this Agreement and the
USC Agreement, Tracon shall pay to Cell-Matrix, in accordance with the terms and conditions set
forth in the USC Agreement, all royalties, annual minimum royalties, and patent filing, prosecution
and maintenance costs that shall be owing by Cell-Matrix under the USC Agreement as a result of the
sublicense grant to Tracon under the USC Patent Rights, or the filing, prosecution and maintenance
or the development and commercialization of a Product pursuant to this Agreement (“USC
Payments”). Cell-Matrix shall timely pay to USC in full any and all USC Payments. Any
royalties payable under the USC Agreement shall be calculated in accordance with the “NET SALES
PRICE” definition set forth on Exhibit E-1. The amount of any minimum annual royalty paid
by Tracon hereunder (as described in Section 4(b) of the USC Agreement) shall be creditable against
any pass-through royalty payments made by Tracon pursuant to this Section 5.6.1. Tracon will make
any milestone or other fixed payments due to Cell-Matrix pursuant to this Section 5.6.1 at least
[***] prior to the date such payments are due to USC pursuant to the terms of the USC Agreement.

               5.6.2 AME Agreement. Subject to the terms and conditions of this Agreement and the
AME Agreement, Tracon shall pay to Cell-Matrix, in accordance with the terms and conditions set
forth in the AME Agreement, all royalties, licensing fees and milestone payments that shall be
owing by Cell-Matrix under the AME Agreement as a result of the rights granted to Tracon under the
Cell-Matrix Patent Rights or the development and commercialization of a Product pursuant to this
Agreement. Any royalties payable under the AME Agreement shall be calculated in accordance with
the “Net Sales” definition set forth on Exhibit E-2, including the provision of Section
4.1.3 of the AME Agreement. Tracon will make any milestone or other fixed payments due to
Cell-Matrix pursuant to this Section 5.6.2 at least [***] prior to the date such payments are due
to AME pursuant to the terms of the AME Agreement.

               5.6.3 [***] License Agreement.

                    (a) If the [***] Patent Rights and the [***] Know-How Rights, as applicable, are included
within the scope of the Licensed IP Rights pursuant to Section 3.7, then subject to the terms and
conditions of this Agreement, Tracon shall pay to Cell-Matrix, in accordance with the terms and
conditions set forth in the [***] License Agreement, all royalties, milestone payments and
licensing fees that shall be owing by Cell-Matrix as a result of the rights granted to Tracon under
the [***] Patent Rights and [***] Know-How Rights, as applicable or the development and
commercialization of a Product pursuant to this Agreement. Cell-Matrix shall timely pay to [***]
in full any and all such payments due under the [***] Agreement and the [***] License
Agreement. Any royalties payable under the [***] License Agreement shall be calculated in
accordance with the “Net Sales” definition set forth in said agreement. Tracon will make any
milestone or other fixed payments due to Cell-Matrix pursuant to this Section 5.6.3 at least [***]
prior to the date such payments are due to [***] pursuant to the terms of the [***] License
Agreement.

 

			
	***	 	Certain information on this page has been
omitted and filed separately with the Commission. Confidential treatment has
been requested with respect to the omitted portions.

-18-

 

                    (b) Termination of License under [***] Patent and Know-How Rights. Tracon shall
notify Cell-Matrix if at any time during the term of this Agreement it ceases to practice all of
the [***] Patent Rights and [***] Know-How Rights licensed under this Agreement. Upon
receipt of such notification, Cell-Matrix shall terminate Tracon’s rights under this Agreement with
respect to the [***] Patent Rights and [***] Know-How Rights and the Licensed IP Rights shall
exclude the [***] Patent Rights and [***] Know-How Rights. In connection with such termination,
Tracon shall comply with all requirements imposed under the [***] Agreement or the [***] License
Agreement, as applicable, and requests of Cell-Matrix reasonably related to such termination
(including, without limitation, relating to the transfer of intellectual property rights, materials
and information), and Tracon shall agree not to practice any of the [***] Patent Rights and [***]
Know-How Rights following such termination.

     6. ROYALTY REPORTS AND ACCOUNTING

          6.1 Royalty Reports. Within [***] after the end of each calendar quarter during the
term of this Agreement following first to occur of the First Commercial Sale of a Product and the
receipt by Tracon of Sublicensing Revenues, Tracon shall furnish to Cell-Matrix a quarterly written
report showing in reasonably specific detail (a) the calculation of Net Sales during such calendar
quarter, including amounts payable under the Cell-Matrix In-Licenses, and any additional
information to be provided to the other party under the applicable Cell-Matrix In-License; (b) the
calculation of Sublicensing Revenues for such quarter; (c) the calculation of the royalties, if
any, that shall have accrued based upon such Net Sales and payments based upon Sublicensing
Revenues; (d) the withholding taxes, if any, required by law to be deducted with respect to such
sales; and (e) the exchange rates, if any, used in determining the amount of United States dollars.
With respect to sales of Products invoiced in United States dollars, the gross sales, Net Sales
and royalties payable shall be expressed in United States dollars. Each such royalty report shall
include a similar calculation for all royalties payable by Tracon to Cell-Matrix pursuant to
Section 5.6. With respect to (i) Net Sales invoiced in a currency other than United States dollars
and (ii) cash consideration paid in a currency other than United States dollars by Tracon’s
sublicensees hereunder, all such amounts shall be expressed both in the currency in which the
distribution is invoiced and in the United States dollar equivalent. The United States dollar
equivalent shall be calculated using the average of the exchange rate (local currency per US$1)
published in The Wall Street Journal, Western Edition, under the heading “Currency Trading”
on the last business day of each month during the applicable calendar quarter; provided, that the
conversion of currency used for calculation of royalties due pursuant to the USC Agreement shall be
based on the exchange rate published on the last business day of the applicable quarter in The
Wall Street Journal, Western Edition, under the heading “Currency Trading”.

          6.2 Audits.

               6.2.1 Upon the written request of Cell-Matrix and not more than [***], Tracon shall permit an
independent certified public accounting firm of nationally recognized standing selected by
Cell-Matrix and reasonably acceptable to Tracon, at Cell-Matrix’s expense,

 

			
	***	 	Certain information on this page has been
omitted and filed separately with the Commission. Confidential treatment has
been requested with respect to the omitted portions.

-19-

 

to have access during normal business hours to such of the financial records of Tracon as may
be reasonably necessary to verify the accuracy of the payment reports hereunder for the [***]
immediately prior to the date of such request (other than records for which Cell-Matrix has already
conducted an audit under this Section).

               6.2.2 If such accounting firm concludes that additional amounts were owed during the audited
period, Tracon shall pay such additional amounts within [***] after the date Cell-Matrix delivers
to Tracon such accounting firm’s written report so concluding. The fees charged by such accounting
firm shall be paid by Cell-Matrix; provided, however, if the audit discloses that the royalties
payable by Tracon for such period are more than [***] percent ([***]%) of the royalties
actually paid for such period, then Tracon shall pay the reasonable fees and expenses charged by
such accounting firm.

               6.2.3 Cell-Matrix shall cause its accounting firm to retain all financial information subject
to review under this Section 6.2 in strict confidence; provided, however, that Tracon shall have
the right to require that such accounting firm, prior to conducting such audit, enter into an
appropriate non-disclosure agreement with Tracon regarding such financial information. The
accounting firm shall disclose to Cell-Matrix only whether the reports are correct or not and the
amount of any discrepancy. No other information shall be shared. Cell-Matrix shall treat all such
financial information as Tracon’s Confidential Information

     7. PAYMENTS

          7.1 Payment Terms. Royalties shown to have accrued by each royalty report provided
for under Section 6.1 above shall be due on the date such royalty report is due. Payment of
royalties in whole or in part may be made in advance of such due date. All milestone payments and
other payments specifically set forth in this Agreement shall be in U.S. Dollars.

          7.2 Exchange Control. If at any time legal restrictions prevent the prompt remittance
of part or all royalties with respect to any country in the Territory where the Product is sold,
Tracon shall have the right, in its sole discretion, to make such payments by depositing the amount
thereof in local currency to Cell-Matrix’s account in a bank or other depository institution in
such country. If the royalty rate specified in this Agreement should exceed the permissible rate
established in any country, the royalty rate for sales in such country shall be adjusted to the
highest legally permissible or government-approved rate.

          7.3 Withholding Taxes. Tracon shall be entitled to deduct the amount of any
withholding taxes or value-added taxes or other similar taxes, levies or charges, other than United
States taxes, payable by Tracon, its Affiliate or sublicensees, or any taxes required to be
withheld or paid by Tracon, its Affiliate or sublicensees, to the extent Tracon or its sublicensees
pay such taxes, charges or levies to the appropriate governmental authority on behalf of
Cell-Matrix. Tracon shall use all reasonable efforts to minimize any such taxes, levies or charges
required to be withheld or paid on behalf of Cell-Matrix. Tracon promptly shall deliver to
Cell-Matrix proof of all such taxes, levies and other charges, together with copies of all

 

			
	***	 	Certain information on this page has been
omitted and filed separately with the Commission. Confidential treatment has
been requested with respect to the omitted portions.

-20-

 

communications from or with such appropriate governmental authority with respect thereto.
Tracon agrees to assist Cell-Matrix in claiming exemption from such deductions or withholdings
under double taxation or similar agreement or treaty from time to time in force and in minimizing
the amount required to be so withheld or deducted, including using reasonable efforts to obtain, as
applicable, a tax exemption certificate. If, solely as a result of any change in corporate status
or location of Tracon, or permitted assignment of this Agreement, a withholding tax or value added
tax, or similar tax, levy or charge becomes due on payments from Tracon to Cell-Matrix and
Cell-Matrix is not able to claim a credit or reimbursement for such tax, levy or charge, in whole
or in part, then Tracon shall pay [***] such amount not credited or reimbursed to
Cell-Matrix upon delivery of an invoice by Cell-Matrix.

          7.4 Late Payments. Any amount owed by Tracon to Cell-Matrix under this Agreement that
is not paid within the applicable time period set forth herein shall accrue interest at the rate of
the prime rate, federal funds (as reported in The Wall Street Journal, Western Edition, as
of the due date) plus [***] percent ([***]%) or, if lower, the highest rate permitted under
applicable law.

     8. RESEARCH AND DEVELOPMENT OBLIGATIONS

          8.1 Development Activities. Tracon shall have the responsibility for, and shall bear
all of its costs for, its research, development and preclinical activities for the Product in the
Territory (including the development of the manufacturing process and the manufacture of clinical
trial materials) and the filing of Registrations of the Product in the Territory. Tracon shall use
commercially reasonable efforts to conduct such research, development and preclinical activities as
Tracon determines are necessary or desirable to obtain regulatory approval to manufacture and
market the Product, and Tracon shall use commercially reasonable efforts to develop and obtain
regulatory approval to market the Product in the Territory.

          8.2 Manufacturing and Commercialization. Tracon shall have the responsibility for,
and shall bear all costs for, the manufacture of Products and, following approval to commence
marketing of a Product in a country in the Territory, the commercialization activities for the
Product in the Territory. Tracon shall use commercially reasonable efforts to commercialize and
fill market demand for Products in each country in the Territory. To the extent required under the
USC Agreement and the requirements of the Bayh-Dole Act, Products used or sold in the United States
shall be manufactured substantially in the United States, unless a written waiver is obtained in
advance from the relevant U.S. federal agency. Tracon shall perform, and shall ensure that its
Affiliates, sublicensees, and third party contractors perform its research, development,
preclinical, clinical, manufacturing and commercial activities under this Agreement in compliance
with applicable laws, rules, and regulations.

          8.3 Development Milestones. Without limiting the generality of Sections 8.1 and 8.2,
Tracon, its Affiliate or its sublicensee shall satisfy each of the following development milestones
(each a “Development Milestone”):

 

			
	***	 	Certain information on this page has been
omitted and filed separately with the Commission. Confidential treatment has
been requested with respect to the omitted portions.

-21-

 

                    (a) Onset of a Phase I Clinical Trial for a D93 Product by the end of [***];

                    (b) Onset of a Phase IIa Clinical Trial for [***] a D93 Product [***] within
[***] following the delivery to Tracon of the final clinical study report for a Phase I
Clinical Trial for the applicable Product;

                    (c) Onset of a Phase IIb Clinical Trial for [***] a D93 Product [***] within [***] following
delivery to Tracon of the final clinical study report for a Phase IIa Clinical Trial for the
applicable Product;

                    (d) Onset of a Phase III Clinical Trial for [***] a D93 Product [***] within [***] following
delivery to Tracon of the final clinical study report for a Phase IIb Clinical Trial for the
applicable Product;

                    (e) file a BLA for [***] a D93 Product [***] within [***] following the delivery to Tracon of
a final clinical study report for a Phase III Clinical Trial for the applicable Product; and

                    (f) First Commercial Sale for [***] a D93 [***] within [***] following receipt of approval of
a BLA for the applicable Product.

     Notwithstanding anything to the contrary, in no event shall it take Tracon more [***]
following the final dosing of the final patient in each of the foregoing clinical trials in which
to effect its receipt of the associated clinical study report.

     Without prejudice to any remedies as provided in this Agreement and appropriate laws, in the
event Tracon or its sublicensee fails to achieve a Development Milestone, and such failure was not
due to reason(s) beyond their reasonable control, Cell-Matrix shall have the right to terminate
this Agreement. For the avoidance of doubt and without prejudice to other reasons that may be
deemed beyond the reasonable control of Tracon or its sublicensee, should Tracon’s or its
sublicensee’s failure to achieve a Development Milestone be caused by (a) [***] that Tracon or its
sublicensee [***], that Tracon or its sublicensee [***] of any Product, that Tracon or its
sublicensee [***], or that Tracon or its sublicensee [***] of any Product; or (b) the inability of
Tracon or its sublicensee to [***] due to [***] of Tracon or its sublicensee, then such evidence
presented to Cell-Matrix by Tracon or its sublicensee shall be deemed by Cell-Matrix to be beyond
Tracon’s or its sublicensee’s reasonable control and Cell-Matrix shall grant Tracon or its
sublicensee reasonable time extensions or milestone adjustments to the extent of any such delay
(the “Excused Delay”).

     If Tracon or its sublicensee fails to achieve a Development Milestone, taking into account any
Excused Delay to which Tracon or its sublicensee may be entitled, then Cell-Matrix shall grant to
Tracon or its sublicensee additional time in which to achieve such Development Milestone subject to
the payment to Cell-Matrix of [***] Dollars ($[***]) for each [***] extension period (each, an
“Extension Period”) that is requested by Tracon or its sublicensee. In

 

			
	***	 	Certain information on this page has been
omitted and filed separately with the Commission. Confidential treatment has
been requested with respect to the omitted portions.

-22-

 

no event shall Tracon and/or its sublicensee collectively be permitted to have more than
[***] Extension Periods during the term of this Agreement for each Product. For
clarity, nothing in this Section 8.3 or the making of such payments by Tracon shall relieve Tracon
of its obligations under this Agreement, including its diligence obligations under this Article 8,
although it shall extend the time period during which the Development Milestones of this Section
8.3 must be completed by the term of the Extension Period.

          8.4 Recalls. Each party shall promptly notify the other party in writing if it
determines that any event, incident or circumstance has occurred which may result in the need for a
“recall” or “market withdrawal” (as such terms are defined in 21 C.F.R. 7.3 or other similar
national, state or local law or regulation) (hereinafter referred to as a “Recall”) of a
Product or any lot(s) thereof. Tracon shall be responsible for determining whether and upon what
terms and conditions any Product shall be Recalled or otherwise withdrawn from sale to Third
Parties within any country in the Territory. Tracon shall be responsible for discussions with
Competent Authorities within the applicable country regarding all aspects of the Recall decision
and the execution thereof. If at any time (i) any Competent Authority in the Territory issues a
request, directive or order for a Recall of a Product in the Territory or (ii) a court of competent
jurisdiction orders a Recall of any Product in the Territory, then Tracon shall be responsible for
implementing such Recall. The expenses arising from such Recall shall be the responsibility of
Tracon.

     9. CONFIDENTIALITY

          9.1 Confidential Information. During the term of this Agreement, and for a period of
[***] following the expiration or earlier termination hereof, each party shall maintain in
confidence all information of the other party that is disclosed by the other party under this
Agreement or was disclosed under the Confidentiality Agreement, including disclosures by
Cell-Matrix or its Affiliates to Paramount under such agreement (the “Confidential
Information”), and shall not use, disclose or grant the use of the Confidential Information
except on a need-to-know basis to those directors, officers, affiliates, employees, permitted
licensees, permitted assignees and agents, consultants, clinical investigators or contractors, to
the extent such disclosure is reasonably necessary in connection with performing its obligations or
exercising its rights under this Agreement. To the extent that disclosure is authorized by this
Agreement, prior to disclosure, each party hereto shall obtain agreement of any such Person to hold
in confidence and not make use of the Confidential Information for any purpose other than those
permitted by this Agreement. Each party shall notify the other promptly upon discovery of any
unauthorized use or disclosure of the other party’s Confidential Information.

          9.2 Permitted Disclosures. The confidentiality obligations contained in Section 9.1
above shall not apply to the extent that (a) any receiving party (the “Recipient”) is
required (i) to disclose information by law, regulation or order of a governmental agency
(including the SEC), a stock exchange on which a party’s shares are traded, or a court of competent
jurisdiction, or (ii) to disclose information to any governmental agency for purposes of obtaining
approval to test or market a product, provided in either case that the Recipient shall

 

			
	***	 	Certain information on this page has been
omitted and filed separately with the Commission. Confidential treatment has
been requested with respect to the omitted portions.

-23-

 

provide written notice thereof to the other party and sufficient opportunity to object to any
such disclosure or to request confidential treatment thereof; or (b) the Recipient can demonstrate
that (i) the disclosed information was public knowledge at the time of such disclosure to the
Recipient, or thereafter became public knowledge, other than as a result of actions of the
Recipient in violation hereof; (ii) the disclosed information was rightfully known by the Recipient
(as shown by its written records) prior to the date of disclosure to the Recipient by the other
party hereunder; (iii) the disclosed information was disclosed to the Recipient on an unrestricted
basis from a source unrelated to any party to this Agreement and not under a duty of
confidentiality to the other party; or (iv) the disclosed information was independently developed
by the Recipient without use of or access to the Confidential Information disclosed by the other
party. Notwithstanding any other provision of this Agreement, Tracon may disclose Confidential
Information of Cell-Matrix relating to information developed pursuant to this Agreement to any
Person with whom Tracon has, or is proposing to enter into, a sublicense of the rights hereunder or
a proposed acquisition of Tracon, as long as such Person has entered into a confidentiality
agreement with Tracon with obligations of confidentiality and non-use that are at least as
stringent as those contained in this Agreement.

          9.3 Terms of this Agreement. Except to the extent disclosures are permitted as
provided in Section 9.2 or Section 9.4, Cell-Matrix and Tracon shall not disclose any terms or
conditions of this Agreement to any Third Party without the prior consent of the other party.

          9.4 Press Release. On the Effective Date of this Agreement, Micromet, Inc. and Tracon
will issue a mutually agreed press release announcing the existence of this Agreement in the form
attached hereto as Exhibit F. For subsequent press releases and other written public
disclosures relating to this Agreement or the parties’ relationship hereunder (each, a “Public
Disclosure”), each party shall use reasonable efforts to submit to the other party a draft of
such Public Disclosures for review and comment by the other party at least [***] business
days prior to the date on which such party plans to release such Public Disclosure, and shall
review and consider in good faith any comments provided in response. If a party is unable to
comply with the foregoing [***] day notice requirement because of a legal obligation or stock
exchange requirement to make more rapid disclosure, such party shall not be in breach of this
Agreement but shall in that case provide notice as promptly as practicable under the circumstances.
A party may publicly disclose, without regard to the preceding requirements of this Section 9.4,
information that was previously disclosed in a Public Disclosure in compliance with such
requirements.

     10. PATENTS

          10.1 Patent Prosecution and Maintenance.

               10.1.1 As between the parties, Cell-Matrix shall have the right to control, at Tracon’s cost,
the preparation, filing, prosecution and maintenance of all patents and patent applications within
the Cell-Matrix Patent Rights using counsel reasonably acceptable to Tracon. Cell-Matrix shall
give Tracon an opportunity to review and comment on the text of each patent

 

			
	***	 	Certain information on this page has been
omitted and filed separately with the Commission. Confidential treatment has
been requested with respect to the omitted portions.

-24-

 

application, office action (including restriction requirements) and substantive correspondence
with the applicable patent office subject to this Section 10.1.1 before filing and shall supply
Tracon with a copy of each patent application as filed, together with its notice of filing date and
serial number. Cell-Matrix shall consider and incorporate in good faith the requests and
suggestions of Tracon with respect to the foregoing and shall keep Tracon informed of progress with
regard to the preparation, filing, prosecution and maintenance of the Cell-Matrix Patent Rights.
Tracon shall cooperate with Cell-Matrix, execute all lawful papers and instruments and make all
rightful oaths and declarations as may be necessary in the preparation, prosecution and maintenance
of all patents and other filings referred to in this Section 10.1.1. If Cell-Matrix, in its sole
discretion, decides to abandon the preparation, filing, prosecution or maintenance of any patent or
patent application in the Cell-Matrix Patent Rights, then Cell-Matrix shall notify Tracon in
writing thereof and following the date of such notice (a) Tracon shall, at its option, be
responsible for and shall control, [***] the preparation, filing, prosecution and maintenance of
such patents and patent applications, and (b) if Tracon does not assume such control, then Tracon
shall thereafter have no license under this Agreement to such patents and patent applications.

               10.1.2 As between the parties, Tracon shall have the sole right to control, at
[***] cost, the preparation, filing, prosecution and maintenance of all patents and
patent applications claiming inventions or discoveries relating to the Products conceived or
reduced to practice by or on behalf of Tracon in the course of developing or commercializing the
Products (the “Tracon Inventions”). Tracon shall provide Cell-Matrix with annual updates
regarding the discovery, conception or reduction to practice of any Tracon Inventions. Tracon
shall give Cell-Matrix an opportunity to review and comment on the text of each such patent
application, office action (including restriction requirements) and substantive correspondence with
the applicable patent office subject to this Section 10.1.2 before filing and shall supply Tracon
with a copy of each patent application as filed, together with its notice of filing date and serial
number. Tracon shall consider and incorporate in good faith the requests and suggestions of
Cell-Matrix with respect to the foregoing and shall keep Cell-Matrix informed of progress with
regard to the preparation, filing, prosecution and maintenance of the such patents and patent
applications.

          10.2 Notification of Infringement. Each party shall notify the other party of any
substantial infringement in the Territory known to such party of any Cell-Matrix Patent Rights and
shall provide the other party with the available evidence, if any, of such infringement.

          10.3 Enforcement of Patent Rights. Tracon, at its sole expense, shall have the right
to determine the appropriate course of action to enforce Cell-Matrix Patent Rights or otherwise
abate the infringement thereof, to take (or refrain from taking) appropriate action to enforce
Cell-Matrix Patent Rights, to defend any declaratory judgments seeking to invalidate or hold the
Cell-Matrix Patent Rights unenforceable, to control any litigation or other enforcement action and
to enter into, or permit, the settlement of any such litigation, declaratory judgments or other
enforcement action with respect to Cell-Matrix Patent Rights, in each case in Tracon’s own name
and, if necessary for standing purposes, in the name of Cell-Matrix and shall consider, in good
faith, the interests of Cell-Matrix in so doing. If Tracon does not, within [***] of receipt of
notice from Cell-Matrix, abate the infringement or file suit to enforce the Cell-Matrix Patent

 

			
	***	 	Certain information on this page has been
omitted and filed separately with the Commission. Confidential treatment has
been requested with respect to the omitted portions.

-25-

 

Rights against an infringing party in a particular country in the Territory, Cell-Matrix shall
have the right to take whatever action it deems appropriate to enforce the Cell-Matrix Patent
Rights; provided, however, that, within [***] after receipt of notice of Cell-Matrix’s intent to
file such suit, Tracon shall have the right to jointly prosecute such suit and to fund up to
[***] the costs of such suit. Notwithstanding anything to the contrary herein, the party
controlling any action covered by this Section 10.3 shall not settle the action or otherwise
consent to an adverse judgment in such action that diminishes the rights or interests of the
non-controlling party or would impose any financial obligation on such non-controlling party
without the prior written consent of the other party. All monies recovered upon the final judgment
or settlement of any such suit to enforce the Cell-Matrix Patent Rights shall be [***], after
reimbursement of expenses, [***].

          10.4 Cooperation. In any suit to enforce and/or defend the License Patent Rights
pursuant to this Section 10, the party not in control of such suit shall, at the request and
expense of the controlling party, cooperate in all respects and, to the extent possible, have its
employees testify when requested and make available relevant records, papers, information, samples,
specimens, and the like.

          10.5 Consequences of Patent Challenge.

               10.5.1 Termination on Patent Challenge. Cell-Matrix shall be permitted to terminate
this Agreement by written notice effective upon receipt if Tracon or its Affiliates directly, or
indirectly through assistance granted to a Third Party (provided that Cell-Matrix shall provide an
opportunity to Tracon to cure within [***] in the event Cell-Matrix becomes aware of such indirect
assistance and if cure is feasible), commence any interference or opposition proceeding, challenge
the validity or enforceability of, or oppose any extension of or the grant of a supplementary
protection certificate with respect to, any patent within the Licensed Patent Rights (each such
action a “Patent Challenge”).

               10.5.2 Sublicensees. Tracon shall include provisions in all agreements granting
sublicenses of Tracon’s rights hereunder providing that if the sublicensee or its Affiliates
undertake a Patent Challenge with respect to any patent within the Licensed Patent Rights under
which the sublicensee is sublicensed, Tracon shall be permitted to terminate such sublicense
agreement (provided that Tracon shall provide an opportunity to such sublicensee to cure within
[***] in the event Tracon becomes aware of such indirect assistance and if cure is feasible). If a
sublicensee of Tracon (or an Affiliate of such sublicensee) undertakes a Patent Challenge of any
such patent under which such Sublicensee is sublicensed, then Tracon upon receipt of notice from
Cell-Matrix of such Patent Challenge shall terminate the applicable sublicense agreement. If
Tracon fails to so terminate such sublicense agreement within [***] of receipt of notice,
Cell-Matrix may terminate this Agreement.

          10.6 Certification Under Drug Price Competition and Patent Restoration Act. Each
party shall immediately give written notice to the other party of any certification of which they
become aware filed pursuant to 21 U.S.C. Section 355(b)(2)(A) (or any amendment or

 

			
	***	 	Certain information on this page has been
omitted and filed separately with the Commission. Confidential treatment has
been requested with respect to the omitted portions.

-26-

 

successor statute thereto) claiming that any Cell-Matrix Patent Rights are invalid or
unenforceable, or that infringement shall not arise from the manufacture, use or sale of a product
by a Third Party.

     11. TERMINATION

          11.1 Expiration. Subject to Sections 11.2 and 11.3 below, this Agreement shall expire
on the expiration of the Royalty Term for all Products in all countries of the Territory. Upon
expiration of this Agreement Tracon shall have a fully paid-up, non-exclusive license under the
Licensed Know-How Rights to conduct research and to develop, make, have made, use, sell, offer for
sale and import Products in the Territory for use in the Field.

          11.2 Termination by Tracon. Tracon may terminate this Agreement, in its sole
discretion, upon [***] prior written notice to Cell-Matrix; provided, however, that Tracon shall
not have the right to terminate this Agreement pursuant to this Section 11.2 prior to the earlier
to occur of (a) payment of the last installment of the amount due for the deliveries actually made
pursuant to Section 4, or (b) delivery to Tracon of a final clinical study report for the first
Phase I Clinical Trial.

          11.3 Termination for Cause. Except as provided in Section 13, Cell-Matrix may
terminate this Agreement upon or after the material breach of any provision of this Agreement by
Tracon if Tracon has not cured such breach within [***] after notice thereof by Cell-Matrix (or
[***] in the case of any non-payment); provided, that if the breach (other than for
non-payment) is not capable of being cured in [***], then such cure period shall be extended for up
to an additional [***] period provided that Tracon is using commercially reasonable efforts to cure
the breach and such breach is reasonably capable of cure during such additional period.

          11.4 Effect of Expiration or Termination. Expiration or termination of this Agreement
shall not relieve the parties of any obligation accruing prior to such expiration or termination,
and the provisions of Sections 2.5, 3.3, 4.2, 5.1(a) and (b), 6.2, 7 (as to any amounts accrued but
unpaid as of the effective date of such expiration or termination), 9, 11.4, 11.5, 12 and 14 shall
survive the expiration or termination of this Agreement. If Tracon has granted a sublicense to a
Third Party under the license granted to Tracon under this Agreement in accordance with Section
3.1, and provided that the Third Party sublicensee is not in breach of its agreement with Tracon or
the terms of this Agreement applicable to Tracon or its sublicensees, Cell-Matrix shall grant a
direct license to any such Third Party sublicensee of Tracon hereunder having the same scope as
such sublicense and on terms and conditions no less favorable to such sublicensee than the terms
and conditions of the applicable sublicense agreement.

          11.5 Technology Transfer Following Termination. Upon any termination of this
Agreement, all of Tracon’s rights and licenses under this Agreement shall terminate, and upon
written request of Cell-Matrix, Tracon shall (a) transfer to Cell-Matrix all of Tracon’s and its
Affiliate’s rights (and the rights of any sublicensee subject to Sections 3.4 and 11.4), in

 

			
	***	 	Certain information on this page has been
omitted and filed separately with the Commission. Confidential treatment has
been requested with respect to the omitted portions.

-27-

 

accordance with a mutually acceptable transition schedule, (1) copies of all data, reports and
materials developed or generated by or on behalf of Tracon in the course of performing activities
under this Agreement, (2) any Registrations and BLAs relating to the Products; (3) the
manufacturing process for any Product and any stock of Product in the possession of Tracon or
Tracon’s contract manufacturer and assign any agreement with such manufacturer to the extent
specifically related to the Product and to the extent assignable (and Tracon shall use commercially
reasonable efforts to seek and obtain such assignment; if such agreement is not assignable, Tracon
shall use commercially reasonable efforts to provide Cell-Matrix with the benefits of such
agreement by sublicense or otherwise to the extent permissible); subject to Cell-Matrix reimbursing
Tracon for the reasonable time Tracon spends and expenses it incurs in relation to such transfer,
and (b) in the event Tracon itself manufactures the Product as of the effective date of such
termination, Tracon shall supply Product to Cell-Matrix at [***] for a period of up to
[***] until Cell-Matrix has established its own source of supply; (c) upon the request of
Cell-Matrix, assign any contracts with any Third Parties to the extent specifically related to the
Product and to the extent assignable (and Tracon shall use commercially reasonable efforts to seek
and obtain such assignment; if such agreement is not assignable, Tracon shall use commercially
reasonable efforts to provide Cell-Matrix with the benefits of such agreement by sublicense or
otherwise to the extent permissible); (d) grant to Cell-Matrix a worldwide, royalty free, exclusive
license (with the right to grant sublicenses through multiple tiers) under any patents and patent
applications owned by Tracon claiming inventions or discoveries specifically relating to the
Products conceived or reduced to practice in the course of developing the Products pursuant to this
Agreement, to develop, make, have made, offer for sale, sell, import and otherwise commercialize
Products in the Territory for use in the Field; and (e) grant to Cell-Matrix a worldwide, license
(with the right to grant sublicenses through multiple tiers) under any patents and patent
applications owned by a sublicensee or to which a sublicensee has a sublicensable right claiming
inventions or discoveries relating to the Products conceived or reduced to practice in the course
of developing the Products pursuant to the Sublicense Agreement, to develop, make, have made, offer
for sale, sell, import and otherwise commercialize Products in the Territory for use in the Field
(it being understood that Cell-Matrix shall be responsible for assuming the royalty, if any,
imposed by such sublicensee in connection with the foregoing license). Cell-Matrix shall reimburse
Tracon’s [***] associated with performing any technology transfer pursuant to this Section 11.5.
Upon the request of Cell-Matrix, Tracon shall provide technical assistance to Cell-Matrix as
Cell-Matrix reasonably requests regarding the foregoing technology transfer for a reasonable period
of time following such transfer. Cell-Matrix shall pay to Tracon its documented reasonable
out-of-pocket costs in providing such technical assistance, and reimburse Tracon for time of
personnel of Tracon engaged in the performance of such services at a reasonable cost to be agreed
by the parties.

     12. INDEMNIFICATION; GUARANTY

          12.1 Indemnification. Tracon shall defend, indemnify and hold Cell-Matrix and its
Affiliates, and any of their directors, officers and employees, harmless from all losses,
liabilities, damages and expenses (including attorneys’ fees and costs) incurred as a result of any
claim, demand, action or proceeding arising out of the development, manufacture, sale or use of

 

			
	***	 	Certain information on this page has been
omitted and filed separately with the Commission. Confidential treatment has
been requested with respect to the omitted portions.

-28-

 

any Product, any breach of this Agreement by Tracon, its Affiliates and its sublicensees, or
the gross negligence or willful misconduct of Tracon in the performance of its obligations under
this Agreement, except in each case to the extent arising from the gross negligence or willful
misconduct of Cell-Matrix, the breach of this Agreement by Cell-Matrix or the development or
manufacture of any Product by Cell-Matrix or its Affiliates prior to the date of this Agreement.

          12.2 Procedure. Cell-Matrix promptly shall notify Tracon of any liability or action
in respect of which Cell-Matrix intends to claim such indemnification, and Tracon shall assume the
defense thereof with counsel selected by Tracon. The indemnity in this Section 12 shall not apply
to amounts paid in settlement of any loss, claim, damage, liability or action if such settlement is
effected without the consent of Tracon, which consent shall not be withheld unreasonably. The
failure to deliver notice to Tracon within a reasonable time after the commencement of any such
action, if prejudicial to its ability to defend such action, shall relieve Tracon of any liability
to Cell-Matrix under this Section 12 to the extent prejudiced, but the omission so to deliver
notice to Tracon shall not relieve it of any liability that it may have to Cell-Matrix otherwise
than under this Section 12. Cell-Matrix under this Section 12, its employees and agents, shall
cooperate fully with Tracon and its legal representatives in the investigation and defense of any
action, claim or liability covered by this indemnification.

          12.3 Insurance. Tracon shall maintain product liability insurance with respect to the
research, development, manufacture and sales of Products by Tracon in such amount as Tracon
customarily maintains with respect to the research, development, manufacture and sales of its
similar products. Tracon shall maintain a comprehensive general liability policy of insurance
(including both product liability coverage and broad form contractual liability coverage) having at
least the following coverage amounts for so long as it continues to research, develop, manufacture
or sell any Products, and thereafter for so long as Tracon customarily maintains insurance covering
the research, development, manufacture or sale of its similar products (but in any event at
[***] thereafter): (i) upon the Effective Date, single limit coverage of not less than
$[***] per incident and $[***] annual aggregate; (ii) in any country where the Products, or any
modification thereof, are utilized in human clinical trials, single limit coverage of not less than
$[***] per incident and $[***] annual aggregate; and (iii) in any country where the Products, or
any modification thereof, are administered to humans, manufactured or distributed for any purpose
other than human clinical trials, single limit coverage of not less than $[***] per incident and
$[***] annual aggregate.

          12.4 Guaranty. In consideration of the rights granted to Tracon under this Agreement,
Paramount irrevocably and unconditionally guarantees the full and timely performance and payment by
Tracon, and each of its successors and assigns, of all its obligations under this Agreement, as now
or hereafter amended, restated, supplemented or otherwise modified from time to time, in favor of
Cell-Matrix and each of its successors and assigns, and hereby undertakes that if Tracon, or its
successors or assigns, shall in any respect fail to perform and observe all of the terms,
provisions, conditions and stipulations of this Agreement (the “Obligations”), Paramount
shall perform or have performed all such Obligations as required by this Agreement without any
requirement that Cell-Matrix first proceed against Tracon or resort

 

			
	***	 	Certain information on this page has been
omitted and filed separately with the Commission. Confidential treatment has
been requested with respect to the omitted portions.

-29-

 

to any other means to collect or receive the benefit of the Obligations. Notwithstanding
anything to the contrary herein, Paramount’s obligations under this Section 12.4 shall expire on
the earlier of the following to occur: (a) the date on which Tracon [***] of at least
[***] Dollars ($[***]) as confirmed in writing by [***]; or (b) the date upon which
Tracon ceases to be an Affiliate of Paramount.

     13. FORCE MAJEURE

     Neither party shall be held liable or responsible to the other party nor be deemed to have
defaulted under or breached this Agreement for failure or delay in fulfilling or performing any
term of this Agreement to the extent, and for so long as, such failure or delay is caused by or
results from causes beyond the reasonable control of the affected party including but not limited
to fire, floods, embargoes, war, acts of war (whether war be declared or not), acts of terrorism,
insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, acts of God
or acts, omissions or delays in acting by any governmental authority or the other party.

     14. MISCELLANEOUS

          14.1 Notices. Any consent, notice or report required or permitted to be given or made
under this Agreement by one of the parties hereto to the other party shall be in writing, delivered
by any lawful means to such other party at its address indicated below, or to such other address as
the addressee shall have last furnished in writing to the addressor and (except as otherwise
provided in this Agreement) shall be effective upon receipt by the addressee.

	 	If to Cell-Matrix: 	 	Cell-Matrix, Inc.

2110 Rutherford Road

Carlsbad, CA 92008

Attention: President

	 
	 	With a copy to: 	 	Micromet, Inc.

6707 Democracy Boulevard

Bethesda, MD 20817

Attention: General Counsel
	 
	 	If to Tracon: 	 	Tracon Pharmaceuticals, Inc.

4510 Executive Drive, Suite 330

San Diego, CA 92121

Attention: General Counsel

	 
	 	If to Paramount: 	 	Paramount Biosciences, LLC

4365 Executive Drive, Suite 1500

San Diego, CA 92121

Attention: General Counsel

 

			
	***	 	Certain information on this page has been
omitted and filed separately with the Commission. Confidential treatment has
been requested with respect to the omitted portions.

-30-

 

          14.2 Governing Law. This Agreement shall be governed by and construed in accordance
with the laws of the State of New York, without regard to the conflicts of law principles thereof.

          14.3 Arbitration. Any dispute, controversy or claim initiated by either party arising
out of, resulting from or relating to this Agreement, or the performance by either party of its
obligations under this Agreement (other than (a) any dispute, controversy or claim regarding the
validity, enforceability, claim construction or infringement of any patent rights, or defenses to
any of the foregoing, or (b) any bona fide third party action or proceeding filed or instituted in
an action or proceeding by a Third Party against a party to this Agreement), whether before or
after termination of this Agreement, shall be finally resolved by binding arbitration. Whenever a
party shall decide to institute arbitration proceedings, it shall give written notice to that
effect to the other party. Any such arbitration shall be conducted under the Commercial
Arbitration Rules of the American Arbitration Association by a panel of three arbitrators appointed
in accordance with such rules. Any such arbitration shall be held in Washington, D.C. The
arbitrators shall have the authority to grant specific performance and to allocate between the
parties the costs of arbitration in such equitable manner as they determine. Judgment upon the
award so rendered may be entered in any court having jurisdiction or application may be made to
such court for judicial acceptance of any award and an order of enforcement, as the case may be.
In no event shall a demand for arbitration be made after the date when institution of a legal or
equitable proceeding based upon such claim, dispute or other matter in question would be barred by
the applicable statute of limitations. Notwithstanding the foregoing, either party shall have the
right, without waiving any right or remedy available to such party under this Agreement or
otherwise, to seek and obtain from any court of competent jurisdiction any interim or provisional
relief that is necessary or desirable to protect the rights or property of such party, pending the
selection of the arbitrators hereunder or pending the arbitrators’ determination of any dispute,
controversy or claim hereunder.

          14.4 Assignment. Tracon shall not assign any of its rights or obligations under this
Agreement without the prior written consent of Cell-Matrix; provided, however, that
Tracon may, without such consent, assign this Agreement in its entirety and all of its rights and
obligations hereunder (a) to an Affiliate or (b) in connection with the transfer or sale of all or
substantially all of its business, or in the event of its merger, consolidation, change in control
or similar transaction. Any permitted assignee shall assume all obligations of its assignor under
this Agreement. For clarity, Cell-Matrix shall have the right to assign any of its rights and
obligations under this Agreement. Each party shall provide written notice to the other party
following any assignment of this Agreement.

          14.5 Waivers and Amendments. No change, modification, extension, termination or
waiver of this Agreement, or any of the provisions herein contained, shall be valid unless made in
writing and signed by duly authorized representatives of the parties hereto.

          14.6 Entire Agreement. This Agreement embodies the entire agreement between the
parties and supersedes any prior representations, understandings and agreements between the parties
regarding the subject matter hereof. There are no representations, understandings or agreements,
oral or written, between the parties regarding the subject matter

-31-

 

hereof that are not fully expressed herein. The parties hereby agree and acknowledge that the
Confidentiality Agreement shall be terminated as of the date hereof and that information disclosed
thereunder is subject to the terms of this Agreement as described in Section 9.

          14.7 Severability. Any of the provisions of this Agreement which are determined to be
invalid or unenforceable in any jurisdiction shall be ineffective to the extent of such invalidity
or unenforceability in such jurisdiction, without rendering invalid or unenforceable the remaining
provisions hereof and without affecting the validity or enforceability of any of the terms of this
Agreement in any other jurisdiction.

          14.8 Waiver. The waiver by either party hereto of any right hereunder or the failure
to perform or of a breach by the other party shall not be deemed a waiver of any other right
hereunder or of any other breach or failure by said other party whether of a similar nature or
otherwise.

          14.9 Independent Contractors. Each party hereby acknowledges that the parties shall
be independent contractors and that the relationship between the parties shall not constitute a
partnership, joint venture or agency. Neither party shall have the authority to make any
statements, representations or commitments of any kind, or to take any action, which shall be
binding on the other party.

          14.10 Counterparts. This Agreement may be executed in two or more counterparts, each
of which shall be deemed an original, but all of which together shall constitute one and the same
instrument.

          14.11 Construction. Except where the context otherwise requires, wherever used, the
singular will include the plural, the plural the singular, and the use of any gender will be
applicable to all genders. Unless used in combination with the word “either,” the word “or” is
used throughout this Agreement in the inclusive sense (and/or). Unless expressly provided
otherwise, references to Sections are references to Sections of this Agreement. The captions of
this Agreement are for convenience of reference only and in no way define, describe, extend or
limit the scope or intent of this Agreement or the intent of any provision contained in this
Agreement. The term “including” as used in this Agreement will mean including, without limiting the
generality of any description preceding such term. No rule of strict construction will be applied
against either Party. Unless expressly provided in this Agreement to the contrary, all time
limits, notice periods, deadlines or the like described in this Agreement will be governed by the
follow parameters: (i) for all time periods that are 5 days in length or less, such periods will be
deemed to be business days, and (ii) for all time periods greater than 5 days in length will be
deemed to be calendar days.

[Signature Page Follows]

-32-

 

     IN WITNESS WHEREOF, the parties have executed this Agreement effective as of the
Effective Date.

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	CELL-MATRIX, INC.	 	 	 	TRACON PHARMACEUTICALS, INC.	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	By:	 	/s/ Christian Itin	 	 	 	By:	 	/s/ Charles P. Theuer	 	 
	 	 	 	 	 	 	 	 	 	 	 
	 

	 	Name:
	 	Christian Itin
	 	 	 	 	 	Name:
	 	Charles P. Theuer, M.D., Ph.D.	 	 
	 

	 	Title:
	 	President
	 	 	 	 	 	Title:
	 	President and Chief Executive Officer	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	MICROMET, INC. *	 	 	 	PARAMOUNT BIOSCIENCES, LLC **	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	By:	 	/s/ Christian Itin	 	 	 	By:	 	/s/ Bertrand C. Liang	 	 
	 	 	 	 	 	 	 	 	 	 	 
	 

	 	Name:
	 	Christian Itin
	 	 	 	 	 	Name:
	 	Bertrand C. Liang, M.D., M.B.A.	 	 
	 

	 	Title:
	 	President & CEO
	 	 	 	 	 	Title:
	 	Vice Chairman	 	 
	 
*solely for the purpose of Section 2.2
	 	 	 	 
**solely for the purpose of Sections 12.4, 14.1, and 14.2	 	 

	 	 	 	 	 
	MICROMET, AG *

 	 	 
	By:  	/s/ Patrick Baeuerle
 	 	 
	 	Name:  	Patrick Baeuerle 	 	 
	 	Title:  	CSO 	 	 
	 
	 	 	 
	By:  	/s/ Jens Hennecke
 	 	 
	 	Name:  	Jens Hennecke 	 	 
	 	Title:  	VP, Business Development 	 	 
	 
	*solely for the purpose of Sections
2.2 and 3.7 

-33-

 

EXHIBIT A

Cell-Matrix Patent Rights

[***][***]

	 	 	 	 	 	 	 	 	 
	Application Title	 	Application	 	Publication	 	Filing date	 	Status
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]

[***]

	 	 	 	 	 	 	 	 	 
	 [***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]

	 	[***]
	 	 	 	[***]
	 	[***]
	[***]

	 	[***]
	 	 	 	[***]
	 	[***]

 

			
	***	 	Certain information on this page has been
omitted and filed separately with the Commission. Confidential treatment has
been requested with respect to the omitted portions.

 

 

[***]

	 	 	 	 	 	 	 	 	 
	Application Title	 	Application	 	Publication	 	Filing Date	 	Status
	[***]

	 	[***]
	 	 	 	[***]
	 	[***]

 

			
	***	 	Certain information on this page has been
omitted and filed separately with the Commission. Confidential treatment has
been requested with respect to the omitted portions.

-35-

 

EXHIBIT B

D93 Sequence

[***]

 

			
	***	 	Certain information on this page has been
omitted and filed separately with the Commission. Confidential treatment has
been requested with respect to the omitted portions.

 

 

EXHIBIT C

[***]

[***]

 

			
	***	 	Certain information on this page has been
omitted and filed separately with the Commission. Confidential treatment has
been requested with respect to the omitted portions.

 

 

EXHIBIT D

Specifications 

The Specifications for the following classifications of Materials shall be as follows:

(a) Clinical Trial Grade Materials Consisting of D93

[***]

(b) Master Cell Banks

[***]

(c) Toxicology and Reference Material for D93

[***]

 

			
	***	 	Certain information on this page has been
omitted and filed separately with the Commission. Confidential treatment has
been requested with respect to the omitted portions.

 

 

EXHIBIT E-1

[***]

 

			
	***	 	Certain information on this page has been
omitted and filed separately with the Commission. Confidential treatment has
been requested with respect to the omitted portions.

 

 

EXHIBIT E-2

[***]

 

			
	***	 	Certain information on this page has been
omitted and filed separately with the Commission. Confidential treatment has
been requested with respect to the omitted portions.

 

 

EXHIBIT F

Press Release

Contacts:

Micromet, Inc.

Company: Chris Schnittker, SVP & CFO, (760) 494-4238,
christopher.schnittker@micromet-inc.com

Investors: Susan Noonan, (212) 966-3650, susan@sanoonan.com

Media: Pat Garrison, (917) 322-2567, pgarrison@rxir.com

TRACON Pharmaceuticals, Inc.

Tara Crosson, (212) 554-4351, tcrosson@paramountbio.com

Delia Alvarez, (858) 550-0780 ext. 232, dvaldovinos@traconpharma.com

Micromet and TRACON Pharmaceuticals Sign Exclusive Worldwide License Agreement to Develop and
Commercialize D93, a Humanized Antibody for Cancer Treatment

Start of Phase 1 Clinical Trial Planned for the Second Half of This Year

San Diego, CA — March 16, 2007 — Micromet, Inc. (NASDAQ: MITI), a biopharmaceutical company
focused on the development of novel and proprietary antibody-based products for cancer,
inflammatory and autoimmune diseases, and TRACON Pharmaceuticals, Inc., a privately held
biopharmaceutical company focused on the development of products for cancer treatment, including
agents that inhibit angiogenesis, today announced an agreement granting TRACON exclusive worldwide
rights to develop and commercialize Micromet’s D93 antibody with a novel mode of action for the
treatment of cancer. TRACON Pharmaceuticals was founded in 2005 by Paramount BioSciences, LLC.

“TRACON’s management team, with its specific expertise in the development of antibodies and small
molecules that target angiogenesis, is an excellent partner for the development of D93 and we are
looking forward to the start of clinical trials planned for the second half of this year,” said
Christian Itin, President and Chief Executive Officer of Micromet, Inc.

D93 is a recombinant humanized IgG1 monoclonal antibody that inhibits angiogenesis, tumor cell
growth and metastasis by targeting cleaved collagen, which is predominantly produced in the
extracellular matrix of tumors. Preclinical studies indicate that D93 has the potential to treat
different types of cancer as a single agent and in combination with chemotherapeutics. Because of
its anti-angiogenic activity, D93 may also provide a new therapeutic approach for other diseases
involving neo-vascularization such as wet age-related macular degeneration or proliferative
diabetic retinopathy. In 2006, Micromet filed an IND with the Food and Drug Administration for
clinical testing of D93 in patients with cancer.

“D93 is a first-in-class humanized antibody that will be developed for the treatment of a variety

 

 

of cancers to complement other currently available therapies,” said Charles P. Theuer MD, PhD,
President and CEO of TRACON Pharmaceuticals.

Under the terms of the agreement, TRACON will be responsible for all development and commercial
activities. TRACON plans to initiate a phase 1 clinical trial in the second half of this year.
Under the terms of the agreement, TRACON will pay Micromet upfront and milestone payments of more
than $100 million, if D93 is successfully developed and commercialized. In addition, Micromet will
receive royalties on worldwide sales of D93.

About TRACON Pharmaceuticals

TRACON Pharmaceuticals (www.traconpharma.com) is a privately held biopharmaceutical company focused
on the development of products for cancer treatment, including agents that inhibit angiogenesis
TRACON addresses unmet needs in this arena with product candidates that will complement existing
therapies. The company’s product candidates each target novel disease pathways. TRC105 is an
antibody that binds CD105 to inhibit endothelial cell proliferation in the tumor vasculature (IND
expected in mid-2007). TRC102 is a small molecule that reverses resistance to chemotherapeutics
that is being evaluated in a phase 1 trial and TRC101 is a nanoliposome embedded with ceramide used
to improve the activity and delivery of chemotherapeutics. By developing and commercializing
novel products in underserved indications, TRACON will maximize patient benefit and enhance
shareholder value.

About Paramount BioSciences

Paramount BioSciences, LLC (www.paramountbio.com) is a leading drug development and
healthcare investment firm focused on the in-licensing of novel therapeutics, and the formation of
new biotechnology companies.

About Micromet, Inc.

Micromet, Inc. (www.micromet-inc.com) is a biopharmaceutical company focusing on the development of
novel, proprietary antibody-based products for cancer, inflammatory and autoimmune diseases. Two
product candidates are currently in clinical trials. MT103 (MEDI-538), which is the first product
candidate based on Micromet’s novel BiTE® product development platform, is being evaluated in a
phase 1 clinical trial for the treatment of patients with non-Hodgkins lymphoma. The BiTE® product
development platform is based on a unique, antibody-based format that leverages the cytotoxic
potential of T cells, the most powerful ‘killer cells’ of the human immune system. Adecatumumab
(MT201), a recombinant human monoclonal antibody which targets EpCAM expressing tumors, has
completed two phase 2a clinical trials, one in patients with breast cancer and the other in
patients with prostate cancer. In addition, a phase 1b trial evaluating the safety and tolerability
of MT201 in combination with docetaxel is currently ongoing in patients with metastatic breast
cancer. Micromet has established collaborations with MedImmune and Merck Serono.

Forward-Looking Statements 

 

 

This release contains certain forward-looking statements that involve risks and uncertainties that
could cause actual results to be materially different from historical results or from any future
results expressed or implied by such forward-looking statements. Such forward-looking statements
include statements regarding the intended utilization of product candidates, the conduct and
results of future clinical trials, plans regarding regulatory filings, future research, discovery
of new product candidates, and clinical trials, and partnering activities. Factors that may cause
actual results to differ materially include the risk that product candidates that appeared
promising in early research and clinical trials do not demonstrate safety and/or efficacy in
larger-scale or later clinical trials, the risks associated with regulatory processes, the risks
associated with reliance on outside financing to meet capital requirements, and the risks
associated with reliance on collaborative partners for future revenues under the terms of its
existing collaboration agreements, and for further pre-clinical and clinical studies, development
and commercialization of product candidates. You are urged to consider statements that include the
words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “potential,”
“expects,” “plans,” “anticipates,” “intends,” “continues,” “forecast,” “designed,” “goal,” or the
negative of those words or other comparable words to be uncertain and forward-looking. These
factors and others are more fully discussed in Micromet’s periodic reports and other filings with
the SEC, including the “Risk Factors” sections of such reports.

Any forward-looking statements are made pursuant to Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and, as such, speak
only as of the date made. Micromet and TRACON undertake no obligation to publicly update any
forward-looking statements, whether as a result of new information, future events or otherwise.

###

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00123-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00123-of-00352.parquet"}]]